Today, xCures announced their collaboration with Tyra Biosciences for a real-world biomarker study involving patients with FGFR-mutant bladder cancer receiving Balversa® (erdafitinib) as their standard of care medical therapy. The study is supported by Tyra Biosciences, Inc., a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. This study will investigate a patient’s tumor DNA through their blood and urine samples to provide information on their treatment and what options might be available if their disease worsens.
Search
Recent Posts
See AllSpring has sprung across the U.S., and many of you are probably ready to hit the course and outdoor courts. But a recent injury may be interrupting your golf game or tennis match. If you’re hesitant o
TripleBlind, creator of the most complete and scalable solution for privacy enhancing computation, announced acceptance to present at IEEE’s 42nd International Conference on Distributed Computing Syst
The Mighty, the world's leading health community bringing the patient's voice to life across the healthcare industry, has hired Matthew Michelson, Ph.D. as President. Dr. Michelson is a pioneer in the
